Particularly the introduction of tumor necrosis factor alpha (TNF-alpha) inhibitors (TNFIs) for the treatment of rheumatic disorders and inflammatory bowel diseases (IBD) and more recently the remarkable success of cancer immunotherapy, have been associated with an increase in iatrogenic inflammatory spinal cord disorders (3, 7, 8). The gene discussed is TNF; the disease is rheumatic disorder.